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Take home message:  
This protocol describes the first study testing the feasibility of integrating a comprehensive geriatric 
assessment alongside pulmonary rehabilitation for people with both COPD and frailty, and the 









Rationale: One in five people with COPD also live with frailty. People living with both COPD and 
frailty are at increased risk of poorer health and outcomes, and face challenges to completing 
pulmonary rehabilitation. Integrated approaches that are adapted to the additional context of frailty 
are required.  
Aim: To determine the feasibility of conducting a randomised controlled trial of an integrated 
comprehensive geriatric assessment for people with COPD and frailty starting pulmonary 
rehabilitation.  
Methods: Multicentre, mixed-methods, assessor-blinded, randomised, parallel group, controlled 
feasibility trial (‘Breathe Plus’; ISRCTN13051922). We aim to recruit 60 people aged ≥50 with both 
COPD and frailty referred for pulmonary rehabilitation. Participants will be randomised 1:1 to 
receive usual pulmonary rehabilitation, or pulmonary rehabilitation with an additional 
comprehensive geriatric assessment. Outcomes (physical, psycho-social and service use) will be 
measured at baseline, 90 days and 180 days. We will also collect service and trial process data, and 
conduct qualitative interviews with a sub-group of participants and staff. We will undertake 
descriptive analysis of quantitative feasibility outcomes (recruitment, retention, missing data, 
blinding, contamination, fidelity), and framework analysis of qualitative feasibility outcomes 
(intervention acceptability and theory, outcome acceptability). Recommendations on progression to 
a full trial will comprise integration of quantitative and qualitative data, with input from relevant 
stakeholders. This study has been approved by a UK Research Ethics Committee (Ref:19/LO/1402). 
Summary: This protocol describes the first study testing the feasibility of integrating a 
comprehensive geriatric assessment alongside pulmonary rehabilitation and testing this intervention 












One in five people with COPD are living with frailty (1). Frailty is broadly understood as a 
multidimensional syndrome characterised by decreases in reserve and diminished resistance to 
stressors (2). People with both COPD and frailty are at increased risk of mortality(3, 4) and have 
increased rates of hospitalisation (4) compared to non-frail counterparts. They experience poorer 
physical function, health status and quality of life (4, 5), and have increased anxiety and depression 
symptoms (6).  
Pulmonary rehabilitation typically comprises twice-weekly, supervised, outpatient exercise sessions 
(involving progressive resistance and aerobic training based on individualised prescriptions) over 6-
12 weeks, plus education to support self-management (7). Importantly, pulmonary rehabilitation is 
equally, if not more, efficacious in people living with COPD and frailty: it can improve breathlessness, 
exercise performance, self-reported physical activity levels, anxiety and depression symptoms, and 
health status (6, 8), as well as reducing frailty (6, 9). However, people living with both COPD and 
frailty are less likely to start and complete pulmonary rehabilitation (6). Development and testing 
adapted approaches encouraging engagement with pulmonary rehabilitation and improving 
outcomes for this population are therefore high priorities. 
To develop an adapted approach and our preliminary underpinning intervention theory, we 
conducted qualitative interviews with people living with both COPD and frailty referred for 
pulmonary rehabilitation (10). Participants described continually striving to adapt to 
multidimensional losses associated with COPD and frailty, and variability in support received. While 
all were initially motivated to engage in pulmonary rehabilitation, changeable health and disruptions 
(e.g. exacerbations, worsening comorbidities, other appointments) could interfere with, and 
sometimes erode, their motivation and ability to attend. We then conducted a realist review to 
understand how exercise-based interventions for people with COPD might better address the 
context of frailty (11). We found that successful exercise-based interventions for this group might 
need to foster trusting relationships with participants and a shared understanding of their priorities, 
individualise content to match priorities, have capacity to address multidimensional losses, and offer 
a flexible service delivery approach. Strategies to enable these mechanisms were identified, 
including a potential role for Comprehensive Geriatric Assessment (CGA).  
CGA is a process incorporating a comprehensive, multidimensional review of a person’s medical, 
psychological, functional and social capability, in order to develop individual recommendations and a 
care plan (12). This typically involves treating any reversible causes, reviewing medicines including 
the impact of polypharmacy, providing nutritional support, cognitive assessment, and offering 
exercise training (12). CGAs reduce functional dependency and mortality for older adults across 
inpatient (13) and outpatient settings (14). In frail older adults, coordinated care based on CGA 
recommendations can improve quality of life and function, and reduce hospital admissions (15). 
When introduced alongside other treatments, CGAs may increase capacity to benefit: pre-surgery 
CGAs can reduce post-operative complications and recovery (16) and CGAs delivered prior to 
chemotherapy are associated with increased tolerance and completion (17). Recent work in 
inpatient respiratory rehabilitation has also suggested improved disease-specific health-status and 
reduced exacerbations(18) following a CGA-directed approach.  
Besides exercise, most core components of a CGA are not routinely addressed by outpatient 
pulmonary rehabilitation (7). Integrating these two evidence-based interventions may therefore be 




1), we propose that addition of a CGA at the start of pulmonary rehabilitation may help foster some 
of the mechanisms deemed important by our development work (10, 11). By fostering therapeutic 
alliance and tailored, multidimensional care recommendations, this approach may increase 
engagement with self-management and supportive services, including pulmonary rehabilitation, and 
contribute to improved health and function through increased reserves and adaptation.   
[INSERT FIGURE 1] 
The proposed intervention is inherently complex: it includes multiple interacting components and 
relies on complex behaviours from participants and professionals (19). Moreover, we will be working 
within complex systems, made up of individual, organisational and societal influences (20). As such 
there are multiple uncertainties around the feasibility and acceptability of the intervention, and how 
best to evaluate its impact, that must be addressed prior to an effectiveness trial (20). This study 
aims to determine the feasibility of conducting a randomised controlled trial of an integrated CGA 
for people with COPD and frailty starting pulmonary rehabilitation. Objectives are shown in Table 1.  
Table 1: Study objectives 
# Objective 
1 To explore the acceptability of the intervention for participants and staff  
2 To define, and understand the fidelity of, integrating a comprehensive geriatric 
assessment, including how it differs from and impacts on usual care   
3 To refine the intervention theory around integration of a comprehensive geriatric 
assessment for this population  
4 To estimate the appropriateness of the proposed eligibility criteria and study processes 
in successfully recruiting and retaining participants in the trial  
5 To estimate risk of contamination between trial groups and unblinding in the trial  
6 To explore the appropriateness and acceptability of proposed outcome measures and 




The Breathe Plus feasibility trial will use a multicentre, mixed-method randomised controlled, 
assessor-blind trial design. Participants will be randomised 1:1 to two parallel groups: usual care, or 
usual care plus a CGA. Quantitative intervention and trial data (including process data and 
participant outcome measures at baseline, 90 days and 180 days) will be collected alongside 
qualitative interview data from a subset of participants and staff (Figure 2).   






Participants will be recruited from three outpatient pulmonary rehabilitation services based in 
hospitals in London, UK. Data collection will take place at participants’ place of preference, typically: 
the hospitals, the university, participants’ place of residence, or via telephone.  
 
Participants  
Participants will include people living with both COPD and frailty referred for outpatient pulmonary 
rehabilitation. Full inclusion/exclusion criteria are shown in Table 2.  
Table 2: Inclusion and Exclusion Criteria  
Inclusion criteria  Exclusion criteria  
Adults aged 50 years or older  Lacking mental capacity to provide informed 
consent 
Physician diagnosis of chronic obstructive 
pulmonary disease (in line with GOLD 
criteria(21))  
Unable to communicate verbally and respond 
to questions in written English and no 
interpreters to enable this 
Referred for outpatient pulmonary 
rehabilitation (in line with BTS guidance(7))*  
Receiving specialist geriatric services involving a 
geriatric doctor in previous or upcoming month  
Rockwood Clinical Frailty Scale score of ≥5 (22)  
GOLD = Global initiative for chronic Obstructive Lung Disease; BTS = British Thoracic Society 
*During the coronavirus pandemic, this will be inclusive of standard pulmonary rehabilitation available, 
including supported home-based exercise programmes  
 
The Clinical Frailty Scale is easy to administer in clinical settings and has been shown to be reliable 
and comparable to the Frailty Phenotype (23). As the Clinical Frailty Scale should only be used after a 
formal clinical assessment (24) it will be incorporated alongside usual pre-pulmonary rehabilitation 
assessments. The research team will provide professionals using the Clinical Frailty Scale with 
training, drawing on published resources (25).  
 
Sampling and recruitment 
We will sample participants consecutively from people attending pre-pulmonary rehabilitation 
assessments. These assessments may take place remotely during the coronavirus pandemic. 
Pulmonary rehabilitation staff at each site will check peoples’ eligibility during this assessment and 
introduce them to the study if applicable. Those interested in participating will receive a participant 
information sheet, and a researcher will discuss the study with them in detail. Those agreeing to 
participate will be asked to provide a record of consent. We anticipate recruitment of our target 






Usual care:   
All participants will continue their planned pulmonary rehabilitation course (typically at least twice-
weekly supervised outpatient exercise sessions plus education for at least six weeks; may include 
amended remote-facilitated rehabilitation during the coronavirus pandemic). Usual care may also 
include interactions with specialist and non-specialist health and social care as required (e.g. 
respiratory consultant, GP, other specialists that support comorbid conditions, emergency and/or 
hospital care, and care from integrated COPD nursing teams that support hospital discharge and 
management of exacerbations at home). All usual care contacts are permitted in both trial arms and 
will be recorded as feasibility trial data.  
Comprehensive geriatric assessment:  
In addition to usual care, the intervention group will receive a CGA as soon as possible following 
completion of baseline measures, ideally prior to starting pulmonary rehabilitation. CGA is a process 
comprising a comprehensive assessment, development of a tailored care plan, and follow-up as 
required. We will encourage teams to work with their local materials (e.g. clinic proformas) to align 
intervention delivery with their usual practice. 
The CGA will be led by a geriatric consultant. The initial appointment will typically be delivered as a 
one-to-one face-to-face appointment in an outpatient clinic, lasting approximately one hour (during 
the coronavirus pandemic, remote delivery via video/phone may also be used). This will include a 
full medical assessment and history, and typically a review of functional and psychosocial issues, 
management of geriatric syndromes (e.g. frailty, falls, sarcopenia, incontinence, malnutrition, 
sensory impairment) and/or advance care planning, as relevant for the person. A resulting 
individualised care plan will be communicated back to the participant and relevant health care 
professionals (e.g. GP, pulmonary rehabilitation team), for actioning. In all cases, tailoring of the 
comprehensive geriatric assessment, subsequent follow-up, and decision to discharge will be led by 
the geriatrician.  
Support will be provided for travel where necessary. For two recruiting sites, the geriatric clinic is at 
the same hospital as the pre-pulmonary rehabilitation assessment. For one recruiting site, the 
geriatric clinic is at a different, nearby hospital.  
 
Feasibility outcomes and progression criteria   
Our primary feasibility outcomes relate to intervention fidelity and acceptability. Table 3 lists all 






Table 3: Breathe Plus feasibility outcomes, contributing data and progression criteria  
Obj. Feasibility outcomes Contributing 
data 
Progression criteria 
Green Amber Red 





staff interviews  
Reported as 
acceptable (or can 









*Fidelity of delivery 
of recommendations 
from the CGA 
Participant 
questionnaires 






Defining what and 
how many 
recommendations 
are made in the CGA 
CGA Service 
data   
NA, descriptive 
Defining what does 
usual care comprise  
Participant 
questionnaires 



























at follow-up  
Participation 
data    
≥75% retained at 
3 months 
≥60% retained at 














receive a CGA 
within usual care 
11-20% >20% 
Success of data 
collector blinding  
Participation 
data   
Blinding 
maintained for 
≥85% participants  
84-70% <70% 
6 Acceptability of 
outcome measures 
and their timing 
Participant 
questionnaires 
& interviews  
Missing data of 













CGA = Comprehensive Geriatric Assessment, PR = Pulmonary Rehabilitation, NA = Not Applicable 
* primary focus; Traffic-light progression criteria(26) - Green: likely no concerning issues, Amber: potentially remediable 






Service and trial process data 
Process data will be used to understand intervention delivery, potential impacts on usual care, and 
trial design appropriateness.  
• CGA service delivery (intervention group participants only): CGA date, recommendations,  
and follow-up, including (where applicable) when and who completed the 
recommendations.  
• Pulmonary rehabilitation service delivery (all participants):  number of pulmonary 
rehabilitation sessions attended, adaptations made (e.g. dose reduction, delays in 
completion), and completion of post-pulmonary rehabilitation assessment.  
• Trial process data: trial screening and recruitment rates, participation at each timepoint, 
mode of data collection, missing data, and unblinding.  
 
Participant characteristics and clinical outcomes 
Baseline demographic characteristics will be obtained through routinely collected data from the 
pulmonary rehabilitation teams, and self-reported questionnaires. These will include personal 
characteristics (age, sex, ethnicity), health and function (Forced expiratory volume in one second 
[FEV1] % predicted, Medical Research Council [MRC] dyspnoea, exacerbations, six-minute walk test 
and/or incremental shuttle walk test, comorbidities, smoking status) and social factors (gender, 
living alone or with others, presence of an informal carer, being an informal carer, housing status, 
formal education level, English Indices of Social Deprivation).  
The clinical outcome measures reflecting multiple domains (Table 4) will be collected at baseline, 90 
days and 180 days post-randomisation. In most cases, questionnaires will be completed with support 
from the researcher, but self-completion with return by post will also be allowed. While an in-person 
visit will be sought, all outcomes except physical frailty could be collected by phone if required. 








Table 4: Clinical outcome measures    
Domain 
 







Battery (SPPB) (27) 
Incorporates 4m gait speed, 5 sit-to-stands, and static balance tests. It 
takes approximately 10-15 minutes to complete, requires a floor mark 
for the gait-speed test, chair for sit-to-stand, and a timer, and results in 











This scale contains 20 items measuring the impact of chronic 
respiratory disease across four domains: dyspnoea, mastery, fatigue, 
and emotional function. Each item is scored from 1-7, and the mean 








Activities of Daily 
Living questionnaire 
(29). 
This measure includes 21 self-report items across four domains: 
mobility, kitchen activities, domestic tasks, and leisure activities. Most 
items are scored 0-1 based on responses of doing tasks ‘not at all’, 
‘with help’, ‘alone with difficulty’ or ‘alone easily’ and total scores range 






Euro-Qol 5D-5L This measure contains 5 descriptive items (mobility, self-care, usual 
activities, pain, and anxiety/depression) with a five-point scale from ‘no 
problems’ to ‘unable/extreme problems’, and a visual analogue scale 
asking participants to rate their health from 0 (worst health imaginable) 
to 100 (best health imaginable). Descriptive item scores are converted 
into a single index value for health status, where a high value 
represents higher health status. Scores would also contribute to health 











This is a 14-item questionnaire with two subscales: anxiety (7 items) 
and depression (7 items). Items are scored on a scale of 0 to 3. Items 
are summed creating a maximum score of 21 on each subscale, where 





De Jong Gierveld 
Loneliness Scale (6-
item) (31) 
This shortened version includes 3 items measuring social loneliness, 
and 3 items measuring emotional loneliness, scored as 0 or 1. When 








This measure asks participants about their contacts with hospital and 
community health care services, any investigations or diagnostic tests, 
help from informal carers, and medication and equipment used, over 
the past 3 months. This measure would also contribute to health 







Nested qualitative interviews  
Nested semi-structured qualitative interviews will be conducted with a sub-sample of participants 
and staff to address feasibility objectives 1 (intervention acceptability), 3 (theoretical underpinning) 
and 6 (outcome acceptability)(Table 3).   
• Participant interviews: We will interview approximately 10 intervention group participants 
following their second (90-day) data collection timepoint. Interviewing intervention 
participants only was deemed most appropriate as our primary feasibility objectives relate 
to intervention acceptability. Purposive sampling will be used to obtain maximum variation 
in relation to site and intervention fidelity, with consideration of diversity in terms of living 
status, outcomes, and questionnaire completion where possible. Informal carers will be 
welcome to participate alongside participants. Interviews will explore experiences of the 
intervention and trial participation.  
 
• Staff interviews: We will interview approximately 5 staff involved in the delivery of the trial. 
Purposive sampling will be used to obtain maximum variation in relation to site and team 
type (e.g. pulmonary rehabilitation, geriatrics). Interviews will explore experiences of the 
trial and perceptions of the intervention.  
Interview schedules will be informed by the theoretical framework of acceptability (33) and 
reviewed by relevant stakeholders (people with relevant clinical, academic and/or personal 
experience). Interviews will be digitally audio-recorded. Field notes will record interview flow, 
contextual factors, participant responses, and personal reflections. Stopping of recruitment will be 
based on sufficiency of information power (34) to answer the feasibility objectives.  
Sample size 
We intend to recruit a total of 60 participants (30 to the intervention group, 30 to the control 
group). This sample size was deemed to give an acceptable level of precision for our quantitative 
feasibility outcomes (35). 
Randomisation & allocation concealment  
Randomisation will occur as soon as possible following consent form completion and baseline 
assessment. Eligible participants will be randomly allocated 1:1 to the intervention or control group.  
Randomisation method of minimisation was chosen with factors defined by site (1, 2 and 3), 
breathlessness (MRC dyspnoea 2-3 and 4-5), exacerbations (≥2 and <2 in the past year) and living 
alone status (yes and no), along with an algorithm that contains an element of simple randomisation 
in order to preserve pre-randomisation allocation concealment.  
The authorised researchers will randomise participants via the independent web based 
randomisation system, run by the King’s Clinical Trials Unit, which will automatically email the 
randomisation result to relevant members of the research team (e.g. chief investigator, research 
assistant) in a pre-specified blinded or unblinded format, depending on their role. An unblinded 






It will not be possible to blind participants and intervention providers. Blinded researchers will 
collect follow-up clinical outcome assessments and complete the quantitative analysis.   
Analysis  
Quantitative data 
Data will be entered by authorised researchers into a secure password-protected web-based Elsevier 
MACRO Electronic Data Capture system created in collaboration with the King’s Clinical Trials Unit, 
which will capture a full audit trail of data entry and amendments. At trial end, following verification 
of data accuracy, the dataset will be locked for analysis.  
A single intention-to-treat analysis will occur. Feasibility outcomes (Table 3) will be described using 
proportions and corresponding 95% confidence intervals, or, for continuous variables as 
means/medians and SD/range, depending on the data distribution. Where source data is not already 
quantified (e.g. CGA service notes), inductive content analysis will be used to summarise this 
information.  
Baseline characteristics of the intervention and control participants will be summarised using 
descriptive statistics. Participant flow through the trial will be reported in a Consolidated Standards 
of Reporting Trials (CONSORT) flow diagram. In keeping with the feasibility aims, clinical outcomes 
will be described, but no inferential statistics used. Safety data will also be summarised.  
Qualitative data 
Qualitative interview data will be transcribed verbatim and link-anonymised. Framework analysis(36) 
will be used to explore the three qualitative feasibility outcomes (intervention acceptability, 
intervention theory, and outcome acceptability; Table 3).  
The analysis process will begin with familiarisation with transcripts and field notes. An analytical 
framework will then be developed drawing deductively on the research objectives and relevant 
theoretical frameworks (including our preliminary intervention theory). The analytical framework 
will also be open to inductively-generated participant-raised issues. This framework will be revised 
based on revisiting the original data to ensure fair interpretation, engagement with wider relevant 
literature that may deepen our understanding, and review by relevant stakeholders to encourage a 
more nuanced reading. The analytical framework will then be systematically applied to the dataset, 
charting summarised data in a case-by-theme matrix. We will then map and interpret key findings 
and analytical themes in relation to the feasibility outcomes. The qualitative findings will be 
presented using a narrative approach, incorporating illustrative participant quotes. Although 
presented as a linear process, we will move forwards and backwards through these stages as 
thinking develops and changes (36). Qualitative data will be mixed with the quantitative data during 
interpretation and reporting.  
Integration & recommendations for progression to a full trial  
Progression to the full trial will be determined based on feasibility trial results meeting pre-defined 
criteria (Table 3) within the context of qualitative data (26); in particular, where the qualitative data 




The data will be considered alongside views of key stakeholders including trial team members, 
clinicians involved in its delivery, and people affected by COPD and frailty. Conclusions and key 
recommendations in relation to each feasibility outcome will be reported with justifications, to aid 
transparency around the final decision. 
 
Monitoring adverse events  
All adverse events will be recorded in study database and monitored for duration of the trial. The 
study may be terminated if safety or ethical concerns are raised over the intervention and/or trial 
processes, or if there is a noticeable increase in number of deaths, emergency attendances or 
hospital admissions in either arm, as reviewed and recommended by joint trial management group / 
data monitoring committee at bi-annual meetings or ad-hoc meetings (if necessary). 
 
Patient and public involvement 
Public involvement members affected by COPD and frailty, including members of our project team, 
and members of other relevant local public involvement groups (e.g. at the Cicely Saunders Institute, 
Harefield Breathing Group, and the local Biomedical Research Centre Respiratory group), have been 
involved in the intervention development work (10, 11) and continue to contribute to this feasibility 
trial. To date, we have received public involvement feedback on the trial name, recruitment 
processes, participant information materials, outcome measures, and qualitative interview topic 
guides. Ongoing involvement includes discussing trial progress, troubleshooting arising challenges, 
assisting with the qualitative analysis, seeking their reflections and interpretations in relation to 
findings, and advising on dissemination. At the end of the trial we will use the Guidance for 
Reporting Involvement of Patients and the Public short form(37) to guide a critical reflection on the 
public involvement in the study.  
 
Ethics  
This study has been approved by the London City and East Research Ethics Committee (Ref. 
19/LO/1402). All participants provide a record of informed consent for their participation.  
 
Protocol version and amendments  
This paper reflects version 3.0 of the study protocol dated 25/06/2020. We have made two protocol 
amendments to date. Based on our experience with the first few participants, we allowed qualitative 
interviews to occur earlier (from 90 days onwards, rather than 180 days) to facilitate participation 
and recall. Due to restrictions on in-person contacts during the coronavirus pandemic, we have also 








A plain-English summary will be sent to participants opting to receive this on their consent form. We 
will submit the results for publication in an open-access peer-reviewed journal, with authorship 
eligibility according to the International Committee of Medical Journal Editors criteria(38). Findings 
will be reported following the CONSORT guidelines for pilot and feasibility trials(39) and Template 
for Intervention Description and Replication statement(40). We will further share findings with 
clinical, academic, and public stakeholders across websites, social media, and presentations at local, 
national and international meetings. The full study protocol and anonymised data will be available 
on request.  
 
Discussion  
There is growing recognition of the potential for integration between geriatric and respiratory care 
(41, 42). The Breathe Plus feasibility trial will test the feasibility of integrating two evidence-based 
approaches: comprehensive geriatric assessment and pulmonary rehabilitation. We hope that this 
will both add value to rehabilitation services, and better address frailty and its consequences in 
people with respiratory disease. 
While bringing together two areas of effective respiratory and geriatric care seems a clear 
opportunity to improve outcomes for people with COPD and frailty, in practice it requires integration 
of multiple complex systems. This preliminary work is therefore essential to address the 
uncertainties surrounding joining of established practices, potential benefits and burdens for 
participants and staff, and whether our proposed methods would be capable of capturing such 
impacts in a future effectiveness trial. It has already been necessary to add some flexibility in our 
methods due to coronavirus-related disruptions, and it may be that further adaptations to this 
changing context are required. However, by exploring the intervention theory alongside processes 
and outcomes, we hope we can explore the impact of such changes and inform further context-
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Figure 1: Preliminary intervention theory of integrating a comprehensive geriatric assessment for 
people with COPD and frailty starting pulmonary rehabilitation  
 
Figure 2: Overview of the Breathe Plus feasibility trial design 
 
 
